VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESGO 2021 | Endometrial Cancer Health Outcomes: pembrolizumab for patients with MSI-high endometrial cancer

Vimalanand Prabhu, PhD, Merck, Lansdale, PA, discusses the retrospective, multicenter chart review study, Endometrial Cancer Health Outcomes (ECHO). ECHO looked at real-world outcomes in adult women with MSI-high or dMMR advanced/inoperable endometrial cancer, who had progressed after prior systemic therapy. The majority of these patients received second-line immunotherapy with pembrolizumab and achieved a good prognosis, leading to this regimen becoming standard of care. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

Disclosures

Vimalanand Prabhu is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and shareholder of Merck & Co., Inc., Kenilworth, NJ, USA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter